MCCP
RLAY icon

Mission Creek Capital Partners’s Relay Therapeutics RLAY Stock Holding History

Mission Creek Capital Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-296,802
Closed -$10.3M – 241
2021
Q1 		$10.3M Buy
+296,802
New +$12.9M 1.53% 6

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mission Creek Capital Partners's RLAY Position: Q2 2021 in Review

Mission Creek Capital Partners sold out of Relay Therapeutics (RLAY) in Q2 2021, closing a stake of 296,802 shares — an estimated $10.3M sold.

Mission Creek Capital Partners first reported a position in RLAY in Q1 2021 and held it in 1 quarter. The position peaked at $10.3M in Q1 2021. 125 funds tracked by Wall St. Rank hold RLAY as of Q2 2021.

  • Mission Creek Capital Partners reported no remaining Relay Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Mission Creek Capital Partners sold 296,802 Relay Therapeutics shares in Q2 2021, an estimated $10.3M.
  • Mission Creek Capital Partners first reported a position in Relay Therapeutics in Q1 2021 and held it in 1 quarter.
  • Mission Creek Capital Partners's Relay Therapeutics position peaked at $10.3M in Q1 2021.
  • 125 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2021.

Based on Mission Creek Capital Partners's 13F filing for Q2 2021, filed 13 Aug 2021.